Forge Biologics to Present and Participate at Upcoming Investor Conferences
Ohio Pen/10194062

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that company leadership members will be making presentations and taking one-on-one meetings at three upcoming investor relations conferences.

Jefferies Cell & Genetic Medicine Summit
Friday, September 30, 10:00-10:25 a.m. ET
Presenter: Christina Perry, Senior Vice President and Head, Finance & Investor Relations
Webcast Link: https://wsw.com/webcast/jeff259/forge/2001825

Chardan Genetic Medicines Conference
Monday, October 3, 2:00-2:25 p.m. ET
Presenter: Timothy J. Miller, CEO, President and Co-Founder
Webcast Link: https://wsw.com/webcast/chard14/forge/2063205

More on Ohio Pen

• DivX Empowers Media Enthusiasts with Free Expert Guides for Advanced MP4 Management
• 2025 MBMA Student Design Competition Now Open
• Assent Expands Executive Team to Accelerate Global Growth & Innovation
• The World's Largest Green Economic Revolution Emerges as Nature, Tech, and Finance Converge
• Vinnetwork Unveils Decentralized AI Platform with Vinnetwork(VIN) Token to Challenge Tech Giants' Data Monopoly

SVB Securities Biopharma Private Company Connect
Wednesday, October 26, 2022
Company executives will hold virtual one-on-one meetings with investors during the event. Meetings with the management team may be requested through SVB Securities.

Forge's presentations will be available for 90 days following each event by visiting the Company's Events website at https://www.forgebiologics.com/news/#events.

About Forge Biologics

Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company. Forge's mission is to enable access to life changing gene therapies and help bring them from idea to reality. Forge's 200,000 square foot facility utilizes 20 cGMP suites in Columbus, Ohio, the Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility focused on AAV manufacturing and can host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. To learn more, visit www.forgebiologics.com.

More on Ohio Pen

• Centennial Flyers to Become Colorado's First Launch Customer for All-Electric B23 Energic Aircraft
• Fully Accountable Introduces Interactive Accounting Scorecard to Improve Financial Performance
• Pyro Marketing Opens New Digital Marketing Company in Saint Petersburg to Power Growth for Fitness and Ecommerce Brands
• Dr. John Salerno of Salerno Wellness Introduces Their New Full Body Capsule for Advanced LED Light Therapy Patient Treatments
• Warren County Park District Unveils Bold Strategic Plan to Shape Future of Parks and Green Spaces

Contacts

Media Inquiries
Marina Corleto
Senior Manager, Marketing and Communications
media@forgebiologics.com

Investor Relations
Christina Perry
Senior Vice President, Head of Finance and Investor Relations
Investors@forgebiologics.com

---

Show All News | Report Violation